“Identification Card”: Sites on Histone Modification of Cancer Cell△

doi:10.1016/S1001-9294(16)30001-3

Abstract

Formation of malignant tumor originating from normal healthy cell is a multistep process including genetic and epigenetic lesions. Previous studies of cell line model systems displayed that early important epigenetic events happened in stepwise fashion prior to cell immortalization. Once these epigenetic alterations are integrated into chromatin, they will perform vertical propagation through cell subculture. Hence, status of epigenetics is dramatically important in maintaining of cell identity. Histone modification is another factor of epigenetic alterations during human oncogenesis. Histones, one of main components of chromatin, can be modified post-translationally. Histone tail modifications are regulated by corresponding modification enzymes. This review focuses on the description of relationship between the main sites of histone modification and oncogenesis.

Key words: histone modification, epigenetics, oncogenesis, methylation, histone acetylation, cancer

Chao Huang, Bin Wen. “Identification Card”: Sites on Histone Modification of Cancer Cell [J].Chinese Medical Sciences Journal, 2015, 30(4): 203-209.

References 59

1.	Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28.
2.	Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33:245-54 .
3.	Mikkelsen TS, Hanna J, Zhang X, et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008; 454:49-55.
4.	Jeong HM, Kwon MJ, Shin YK. Overexpression of cancer-associated genes via epigenetic derepression mechanisms in gynecologic cancer. Front Oncol 2014; 4:1-13.
5.	Rogenhofer S1, Miersch H, Göke F, et al. Histone methylation deﬁnes an epigenetic entity in penile squamous cell carcinoma. J Urol 2013; 189:1117-22.
6.	Popovic R, Licht JD. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov 2012; 2:405-13.
7.	Kondo Y, Shen L, Suzuki S, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007; 37:974-83.
8.	Semi K, Matsuda Y, Ohnishi K, et al. Cellular reprogramming and cancer development. Int J Cancer 2013; 132:1240-8.
9.	Vaiopoulos AG, Athanasoula KCh, Papavassiliou AG. Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges. Biochim Biophys Acta 2014; 1842:971-80.
10	Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129:823-37
11	Schneider R, Bannister AJ, Myers FA, et al. Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat Cell Biol 2004; 6:73-7.
12	Heintzman ND, Hon GC, Hawkins RD, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009; 459:108-12.
13	Forn M, Muñoz M, Tauriello DV, et al. Long range epigenetic silencing is a trans-species mechanism that results in cancer specific deregulation by overriding the chromatin domains of normal cells. Mol Oncol 2013; 7:1129-41.
14	Füllgrabe J, Kavanagh E, Joseph B. Histone onco-modifi- cations. Oncogene 2011; 30:3391-403.
15	Lin CY, Lovén J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012; 151:56-67.
16	Kim J, Chu J, Shen X, et al. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008; 132:1049-61.
17	Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hall mark of human cancer. Nat Genet 2005; 37:391-400.
18	Fraga MF, Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle 2005; 4:1377-81.
19	Lin YW, Chen HM, Fang JY. Gene silencing by the polycomb group proteins and associations with cancer. Cancer Invest 2011; 29:187-95.
20	Lee MC, Kuo YY, Chou WC, et al. Gfi-1 is the transcriptional repressor of SOCS1 in acute myeloid leukemia cells. J Leukoc Biol 2014; 95:105-15.
21	Marteau JB, Rigaud O, Brugat T, et al. Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males. BMC Med Genomics 2010; 3:53.
22	Li Q , Wang X, Lu Z, et al. Polycomb CBX7 directly controls trimethylation of histone H3 at lysine 9 at the p16 locus. PLoS One 2010; 5:e13732.
23	Rotili D, Tomassi S, Conte M, et al. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anti- cancer activities. J Med Chem 2014; 57:42-55.
24	Katz TA, Vasilatos SN, Harrington E, et al. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor- induced apoptosis in breast cancer cells. Breast Cancer Res Treat 2014; 146:99-108.
25	Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-72.
26	Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-76.
27	Fetahu IS, Höbaus J, Aggarwal A, et al. Calcium-sensing receptor silencing in colorectal cancer is associated with promoter hypermethylation and loss of acetylation on histone 3. Int J Cancer 2014; 135:2014-23.
28	Wang ZJ, Yang JL, Wang YP, et al. Decreased histone H2B monoubiquitination in malignant gastric carcinoma. World J Gastroenterol 2013; 19:8099-107.
29	Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40:741-50.
30	van Haaften G, Dalgliesh GL, Davies H, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41:521-3.
31	Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011; 21:381-95.
32	Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007; 39:237-42.
33	Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125:315-26.
34	Hinshelwood RA, Melki JR, Huschtscha LI, et al. Aberrant de novo methylation of the 16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. Hum Mol Genet 2009; 18:3098-109.
35	Javierre BM, Rodriguez-Ubreva J, Al-Shahrour F, et al. Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells. Mol Cancer Res 2011; 9:1139-51.
36	Dallosso AR, Øster B, Greenhough A, et al. Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumo- rigenesis through modulation of oncogenic pathways. Oncogene 2012; 31:4409-19.
37	Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150:12-27.
38	Li J, Li G, Xu W. Histone deacetylase inhibitors: an attractive strategy for cancer therapy. Curr Med Chem 2013; 20:1858-86.
39	Seidel C, Florean C, Schnekenburger M, et al. Chromatin- modifying agents in anti-cancer therapy. Biochimie 2012; 94:2264-79.
40	Rajendran P, Kidane AI, Yu TW, et al. HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates. Epigenetics 2013; 8:612-23.
41	Calcagno DQ, Gigek CO, Chen ES, et al. DNA and histone methylation in gastric carcinogenesis. World J Gastroen- terol 2013; 19:1182-92.
42	Koshiishi N, Chong JM, Fukasawa T, et al. p300 gene alterations in intestinal and difuse types of gastric carcinoma. Gastric Cancer 2004; 7:85-90.
43	Kwon MJ, Kim SS, Choi YL, et al. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcino- genesis 2010; 31:974-83.
44	Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002; 32:606-13.
45	Lu R, Wang X, Sun DF, et al. Folic acid and sodium butyrate prevent tumorigenesis in a mouse model of colorectal cancer. Epigenetics 2008; 3:330-5.
46	Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 2007; 17:363-9.
47	Bell EL, Emerling BM, Ricoult SJ, et al. SirT3 suppresses hypoxia inducible factor 1a and tumor growth by inhibiting mitochondrial ROS production. Oncogene 2011; 30:2986-96.
48	Vaiopoulos AG, Kostakis ID, Athanasoula KCh, et al. Targeting transcription factor corepressors in tumor cells. Cell Mol Life Sci 2012; 69:1745-53.
49	Aguilera C, Nakagawa K, Sancho R, et al. c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor complex. Nature 2011; 469:231-5.
50	Lau AT, Lee SY, Xu YM, et al. Phosphorylation of histone H2B serine 32 is linked to cell transformation. J Biol Chem 2011; 286:26628-37.
51	Choi HS, Choi BY, Cho YY, et al. Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res 2005; 65:5818-27.
52	Fournier A, Sasai N, Nakao M, et al. The role of methyl-binding proteins in chromatin organization and epigenome maintenance. Brief Funct Genomics 2012; 11:251-64.
53	Ura S, Masuyama N, Graves JD, et al. Caspase cleavage of MST1 promotes nuclear translocation and chromatin condensation. Proc Natl Acad Sci USA 2001; 98: 10148-53.
54	Ahn SH, Cheung WL, Hsu JY, et al. Sterile 20 kinase phosphorylates histone H2B at serine 10 during hydrogen peroxide-induced apoptosis in S. cerevisiae. Cell 2005; 120:25-36.
55	Ajiro K, Scoltock AB, Smith LK, et al. Reciprocal epigenetic modification of histone H2B occurs in chromatin during apoptosis in vitro and in vivo . Cell Death Differ 2010; 17:984-93.
56	Prigent C, Dimitrov S. Phosphorylation of serine 10 in histone H3, what for J Cell Sci 2003; 116:3677-85.
57	Bode AM, Dong Z. Inducible covalent posttranslational modification of histone H3. Sci STKE 2005; 2005:re4.
58	Zhong Q, Shi G, Zhang Q, et al. Role of phosphorylated histone H3 serine 10 in DEN-induced deregulation of Pol Ⅲ genes and cell proliferation and transformation. Carcino- genesis 2013; 34:2460-9.
59	Binda O. On your histone mark, SET, methylate! Epigenetics 2013; 8:457-63.

[1]	Rongqiang Zhang, Dandan Zhang, Di Zhang, Xiaoli Yang, Qiang Li, Chen Wang, Xuena Yang, Yongmin Xiong. Crosstalk between CpG Methylation and Polymorphisms (CpG-SNPs) in the Promotor Region of DIO2 in Kashin-Beck Disease [J]. Chinese Medical Sciences Journal, 2022, 37(1): 52-59.
[2]	Siwen Ouyang, Weiming Kang. Research Advances in the Role of Keratins in Gastrointestinal Cancer [J]. Chinese Medical Sciences Journal, 2022, 37(1): 73-78.
[3]	Liang Wang, Gang Li, Yun-tao Bing, Mao-lin Tian, Hangyan Wang, Chunhui Yuan, Dianrong Xiu. Does Prior Cancer Have an Influence on the Survival Outcomes of Patients with Localized Pancreatic Neuroendocrine Tumors? [J]. Chinese Medical Sciences Journal, 2021, 36(4): 284-294.
[4]	Wei Yang, Mei Zhang. Biomarkers with Potential Predictive Value for Cardiotoxicity in Anticancer Treatments [J]. Chinese Medical Sciences Journal, 2021, 36(4): 333-341.
[5]	Chen Xu, Huo Xiaofei, Wu Zhe, Lu Jingjing. Advances of Artificial Intelligence Application in Medical Imaging of Ovarian Cancers [J]. Chinese Medical Sciences Journal, 2021, 36(3): 196-203.
[6]	Xu Chen, Hongling Liu, Fenghui Zhao, Zongxian Jiao, Jinsui Wang, Yamei Dang. Wnt5a Plays Controversial Roles in Cancer Progression [J]. Chinese Medical Sciences Journal, 2020, 35(4): 357-365.
[7]	Xiaoqi Zeng, Shanshan Jiang, Yuanyang Peng, Minfeng Liu, Changsheng Ye, Jianyu Dong. Trastuzumab-Induced Severe Thrombocytopenia:A Case Report and Literature Review [J]. Chinese Medical Sciences Journal, 2020, 35(4): 377-382.
[8]	Li Wenxing, Zhang Yanli. Novel Long Non-coding RNA Markers for Prognostic Prediction of Patients with Bladder Cancer [J]. Chinese Medical Sciences Journal, 2020, 35(3): 239-247.
[9]	Wang Zhan, Wang Xu, Wang Wenda, Zheng Guoyang, Guo Hao, Zhang Yushi. Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Predicting Prognosis of Surgically Resectable Urinary Cancers: Systematic Review and Meta-Analysis [J]. Chinese Medical Sciences Journal, 2020, 35(3): 262-271.
[10]	Xu Longming,Dai Shuiping,Zuo Yunxia. Impacts of Preoperative Smoking and Smoking Cessation Time on Preoperative Peripheral Blood Inflammatory Indexes and Postoperative Hospitalization Outcome in Male Patients with Lung Cancer and Surgery Treatment [J]. Chinese Medical Sciences Journal, 2020, 35(2): 170-178.
[11]	Zhang Ling, Sun Lei, Mu Xiaoyan, Ji Youxin. Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer [J]. Chinese Medical Sciences Journal, 2019, 34(4): 292-296.
[12]	Liang Xi, Hu Jingnan, He Jianming. An Optimized Protocol of Azoxymethane-Dextran Sodium Sulfate Induced Colorectal Tumor Model in Mice [J]. Chinese Medical Sciences Journal, 2019, 34(4): 281-288.
[13]	Bao Yi, Mo Juanfen, Wu Jiayuan, Cao Chenxi. Expression of PD1 and BTLA on the CD8⁺ T Cell and γδT Cell Subsets in Peripheral Blood of Non-Small Cell Lung Cancer Patients [J]. Chinese Medical Sciences Journal, 2019, 34(4): 248-255.
[14]	Wang Guorong, Wang Zhiwei, Jin Zhengyu. Application and Progress of Texture Analysis in the Therapeutic Effect Prediction and Prognosis of Neoadjuvant Chemoradiotherapy for Colorectal Cancer [J]. Chinese Medical Sciences Journal, 2019, 34(1): 45-50.
[15]	Liu Qian, Ning Xiaohong, Wang Lei, Liu Wei. Individualized Aromatherapy in End-of-Life Cancer Patients Care: A Case Report [J]. Chinese Medical Sciences Journal, 2018, 33(4): 234-239.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center

“Identification Card”: Sites on Histone Modification of Cancer Cell

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 59

Related Articles 15

Metrics

Recommended 7